A Phase 0/1b, Single Center, Clinical Trial with an Expansion Phase of AZD1390 Plus Fractionated Radiotherapy in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Mar 2025 Timeframe for both primary endpoints has been charged. for Phase 0 primary endpoint, timeframe changed from Day 4 Intraoperative to Phase 0 Intraoperative. For Phase 1b primary endpoint it is changed from '6 month progression-free survival (PFS6) rate measured from the time of surgery to date of recurrence' to 'from the date of Phase 0 surgery to the date of progression'.
14 Mar 2025 Planned End Date changed from 1 Jan 2025 to 1 Sep 2027.
14 Mar 2025 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com